Latest news with #MedicalProducts
Yahoo
4 days ago
- Business
- Yahoo
Zacks Industry Outlook Highlights Envista, BioLife Solutions, InfuSystems and MariMed
For Immediate Release Chicago, IL – August 15, 2025 – Today, Zacks Equity Research discusses Envista Holdings NVST, BioLife Solutions BLFS, InfuSystems Holdings INFU and MariMed MRMD. Industry: Medical Products Link: The Zacks Medical - Products industry is likely to remain under pressure through the rest of 2025. While procedural volumes are stable, growth is slowing and high-cost, advanced procedures face adoption and funding hurdles. Capital spending is uneven, with longer sales cycles and reliance on expensive technologies creating risks. Innovation in electrophysiology, structural heart, and AI imaging is struggling to translate into consistent revenues amid regulatory delays, competition and payer scrutiny. Emerging markets face policy headwinds, notably China's margin-eroding volume-based procurement. Tariffs, component shortages, COVID testing declines and product discontinuations are further squeezing margins. Without a clear demand rebound or easing cost pressures, the risks led to continued underperformance for the sector. However, industry participants, such as Envista Holdings, BioLife Solutions, InfuSystems Holdings and MariMed, have adapted to changing consumer preferences, and most of them are witnessing a rise in their share price. These companies also carry a favorable Zacks Rank. Industry Description The industry includes companies that provide medical products and cutting-edge technologies for healthcare services. These companies are primarily focused on research and development and cater to vital therapeutic areas like cardiovascular, nephrology and urology devices. The increase in procedure volumes is driving sales, particularly for surgical products and services. At the same time, cost-cutting measures are helping companies improve their bottom-line performance. However, the industry's profitability picture is under significant strain. Tariff-related expenses are cutting into margins, forcing companies into complex and costly supply-chain restructuring. Persistent component shortages, though less widespread than in prior years, continue to create inefficiencies and constrain output in certain product lines. Additionally, the sharp drop in COVID-relate Major Trends Shaping the Future of the Medical Products Industry AI, Medical Mechatronics & Robotics: The increasing adoption of minimally invasive, robot-assisted surgeries, automated home care, IT-driven patient management, and value-based payment models underscores the rising influence of AI in the Medical Products sector. At the forefront is mechatronics — a fusion of electronics, machine learning, and mechanical engineering — driving innovation across the industry. Companies are making significant progress in AI, robotics, and medical mechatronics, with robotic surgical platforms enabling less invasive procedures and reducing patient trauma. Meanwhile, 3D printing is reshaping the landscape, now used to produce stem cells, blood vessels, heart tissue, prosthetics and skin. These advances highlight the sector's transformative shift toward precision, personalization and improved clinical outcomes. Rising Demand for IVD: The COVID-19 pandemic led to a rise in global demand for diagnostic testing kits to curb the spread of the virus. Testing became a pressing need, leading to a shift in the IVD product pipeline, with many rapid, point-of-care devices entering development. Diagnostic kit manufacturers not only received emergency use authorization from the FDA but also bolstered production to help address testing shortages. Industry players anticipate significant demand for rapid diagnostic testing in the future and are poised to capitalize on this opportunity. Emerging Markets Hold Promise: Driven by growing medical awareness and rising economic prosperity, emerging economies are experiencing strong demand for medical products. Factors such as aging populations, more relaxed regulatory environments, affordable skilled labor, increasing household wealth, and government investment in healthcare infrastructure make these markets highly attractive to global medical device companies. Zacks Industry Rank The Zacks Medical Products industry falls within the broader Zacks Medicalsector. It currently carries a Zacks Industry Rank #149, which places it in the bottom 39% of more than 250 Zacks industries. The group's Zacks Industry Rank, which is basically the average of the Zacks Rank of all member stocks, indicates bright near-term prospects. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Before we present a few medical product stocks that you may want to consider for your portfolio, let's take a look at the industry's recent stock-market performance and valuation picture. Industry Performance While the industry has outperformed its own sector, it has underperformed the Zacks S&P 500 composite in the past year. Stocks in this industry have collectively risen 5.1% against the Zacks Medical sector's decline of 19.9%. The S&P 500 has increased 17.2% in the same time frame. Industry's Current Valuation On the basis of the forward 12-month price-to-earnings (P/E), which is commonly used for valuing medical stocks, the industry is currently trading at 21.4X compared with the S&P 500's 22.9X and the sector's 18.5X. Over the past five years, the industry has traded as high as 27.4X and as low as 17.9X, with the median being at 22X. 4 Promising Medical Product Stocks Envista Holdings enters the second half of 2025 with momentum from a solid first-half performance, supported by diversified growth across equipment, consumables, and specialty products. Continued strength in orthodontics, particularly Brackets & Wires and Spark Clear Aligners, will be augmented by product launches like Spark Retainers, AI-enhanced DTX Studio Clinic and Implant Direct scanning solutions. Penetration into dental service organizations (DSOs) and double-digit growth in emerging markets remain key levers. Operational improvements, including a 15% G&A reduction and manufacturing expansion in Suzhou, China, support margin resilience and local-for-local supply strategies. Pricing actions and cost controls are expected to offset tariff pressures, while acquisitions add incremental growth. Strong demand in infection prevention, diagnostics, and implants should continue, with the third quarter benefiting from Spark Deferral revenue. Stable dental market conditions, coupled with strategic investments in sales, marketing, and R&D, position Envista to deliver on its raised guidance for 2025. For this Brea, CA-based company, the Zacks Consensus Estimate for 2025 revenues is pinned at $2.61 billion. The consensus estimate for earnings is pegged at $1.12 per share. NVST delivered a trailing four-quarter average negative earnings surprise of 16.50%. Presently, the company sports a Zacks Rank #1 (Strong Buy). BioLife Solution is set to benefit from strong demand recovery in cell and gene therapy (CGT) tools, as customer manufacturing activity continues to normalize. The recent integration of Astero, Sexton, and other acquired technologies expands its bioproduction solutions portfolio, allowing deeper penetration into high-growth biopharma segments. Expansion of the cryo-storage services footprint, particularly through the SciSafe network, positions the company to capture more recurring revenues. Efforts to optimize manufacturing capacity and reduce COGS should support margin expansion. New product launches in media and biopreservation, alongside an expanded international sales presence, will help address broader customer needs. Strategic partnerships with therapy developers are expected to drive higher adoption of integrated workflow solutions. While macro uncertainty and biotech funding volatility remain potential headwinds, BioLife's diversified portfolio, operational efficiencies and exposure to commercial-stage CGT programs provide a solid foundation for growth through year-end. For this Bothell, WA-based company, the Zacks Consensus Estimate for 2025 revenues indicates a year-over-year decline of 11.7%. The consensus estimate for earnings indicates growth of 171.4%. It delivered a trailing four-quarter earnings surprise of 123.61%, on average. Presently, the company sports a Zacks Rank #1. You can see the complete list of today's Zacks #1 Rank stocks here. InfuSystem Holdings' growth trajectory in the second half of 2025 is anchored in its Device Solutions and Patient Services segments. Expansion of oncology and wound care programs, coupled with growing demand for infusion pumps and related disposables, is expected to lift volumes. The company is capitalizing on the broader adoption of negative pressure wound therapy (NPWT) through partnerships with large healthcare providers. A stronger equipment rental base and fleet optimization efforts should further enhance recurring revenue streams. INFU is also investing in service coverage expansion and technology upgrades to improve customer experience and retention. Operational efficiencies from centralized distribution and maintenance hubs are set to reduce turnaround times and lower costs. The integration of new payer contracts and an expanding referral network will support top-line growth. Risks include reimbursement changes and hospital capital spending constraints, but INFU's recurring revenue model and expanding therapeutic reach are positioned to offset these pressures in the near term. Currently, INFU sports a Zacks Rank of 1. For this Rochester Hills, MI-based company, the Zacks Consensus Estimate for 2025 revenues is pegged at $144.2 million. The consensus mark for loss is pinned at 26 cents per share. The company delivered a trailing four-quarter average earnings surprise of 79.17%. MariMed's growth in the remainder of 2025 will be driven by retail expansion, wholesale penetration and new product innovation in the cannabis sector. The opening of new dispensaries in high-traffic markets, along with remodeling existing locations to improve customer flow, is expected to boost sales. The company is scaling cultivation capacity and optimizing yields to meet growing demand while lowering production costs. Expansion of branded product lines, including edibles and wellness offerings, should strengthen shelf presence and margins. Wholesale growth is supported by increasing distribution agreements across multiple states. Investments in automation and processing technology aim to improve consistency and efficiency. Regulatory developments in key states, particularly around adult-use legalization, could provide an upside catalyst. While the industry faces pricing pressure and regulatory uncertainty, MariMed's vertically integrated model, brand strength, and disciplined capital allocation are set to underpin growth in the second half of the year. Currently, MRMD sports a Zacks Rank #1. For this Springfield, MA-based company, the Zacks Consensus Estimate for 2025 loss is pinned at 3 cents per share. The company delivered a trailing four-quarter average earnings surprise of 50.00%. Free: Instant Access to Zacks' Market-Crushing Strategies Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year. Today you can tap into those powerful strategies – and the high-potential stocks they uncover – free. No strings attached. Get all the details here >> Join us on Facebook: Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. Media Contact Zacks Investment Research 800-767-3771 ext. 9339 support@ Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report BioLife Solutions, Inc. (BLFS) : Free Stock Analysis Report InfuSystems Holdings, Inc. (INFU) : Free Stock Analysis Report Envista Holdings Corporation (NVST) : Free Stock Analysis Report MariMed Inc. (MRMD) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
17-07-2025
- Business
- Yahoo
Abbott (ABT) Q2 Earnings and Revenues Top Estimates
Abbott (ABT) came out with quarterly earnings of $1.26 per share, beating the Zacks Consensus Estimate of $1.25 per share. This compares to earnings of $1.14 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +0.80%. A quarter ago, it was expected that this maker of infant formula, medical devices and drugs would post earnings of $1.07 per share when it actually produced earnings of $1.09, delivering a surprise of +1.87%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. Abbott, which belongs to the Zacks Medical - Products industry, posted revenues of $11.14 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.63%. This compares to year-ago revenues of $10.38 billion. The company has topped consensus revenue estimates two times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Abbott shares have added about 16.5% since the beginning of the year versus the S&P 500's gain of 6.5%. What's Next for Abbott? While Abbott has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Abbott was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.34 on $11.42 billion in revenues for the coming quarter and $5.16 on $44.7 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the bottom 30% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. AtriCure (ATRC), another stock in the same industry, has yet to report results for the quarter ended June 2025. The results are expected to be released on July 29. This medical device maker is expected to post quarterly loss of $0.15 per share in its upcoming report, which represents a year-over-year change of +11.8%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. AtriCure's revenues are expected to be $130.15 million, up 11.9% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report AtriCure, Inc. (ATRC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
17-06-2025
- Business
- Yahoo
High Tide Inc. (HITI) Reports Q2 Loss, Tops Revenue Estimates
High Tide Inc. (HITI) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to break-even earnings per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -50%. A quarter ago, it was expected that this company would post a loss of $0.01 per share when it actually produced a loss of $0.02, delivering a surprise of -100%. Over the last four quarters, the company has surpassed consensus EPS estimates just once. High Tide , which belongs to the Zacks Medical - Products industry, posted revenues of $96.94 million for the quarter ended April 2025, surpassing the Zacks Consensus Estimate by 0.22%. This compares to year-ago revenues of $91.6 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. High Tide shares have lost about 26.2% since the beginning of the year versus the S&P 500's gain of 1.6%. While High Tide has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for High Tide: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.02 on $102.27 million in revenues for the coming quarter and -$0.07 on $404.52 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the bottom 37% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Aurora Cannabis Inc. (ACB), another stock in the same industry, has yet to report results for the quarter ended March 2025. The results are expected to be released on June 18. This company is expected to post quarterly earnings of $0.11 per share in its upcoming report, which represents no change from the year-ago quarter. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Aurora Cannabis Inc.'s revenues are expected to be $62.04 million, up 24.1% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report High Tide Inc. (HITI) : Free Stock Analysis Report Aurora Cannabis Inc. (ACB) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
